SCHEMBL298058

SCHEMBL298058

O=C(CN1CCC=C(c2cc(-c3cccc(O)c3)no2)C1)c1cccs1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM5 P08912 1/20 0.44
ADRA2A P08913 1/20 0.44
ADRA2B P18089 1/20 0.44
ADRA2C P18825 1/20 0.44
CHRM3 P20309 1/20 0.44
KCNH2 Q12809 1/20 0.44
TMEM97 Q5BJF2 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
HSD17B1 P14061 1/20 0.42
HSD17B2 P37059 1/20 0.42
ALDH1A1 P00352 7/20 0.40
KDM4E B2RXH2 1/20 0.40
CASP1 P29466 1/20 0.40
NPC1 O15118 4/20 0.39
RAB9A P51151 3/20 0.39
MAPK1 P28482 4/20 0.39
TP53 P04637 3/20 0.39
TSHR P16473 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL298670 0.84 CHRM2 (0.49) CHRM2CHRM4CHRM5ADRA2AADRA2B
SCHEMBL661206 0.78 HSD17B1 (0.42) HSD17B1HSD17B2ALDH1A1NPC1RAB9A
SCHEMBL5728908 0.68 HSD17B1 (0.84) HSD17B1HSD17B2ALDH1A1NPC1RAB9A
SCHEMBL659986 0.65 NPC1 (0.35) ALDH1A1NPC1RAB9AMAPK1TP53
SCHEMBL1180394 0.64 HSD17B1 (0.88) HSD17B1HSD17B2ALDH1A1NPC1RAB9A
Oxalic Acid SCHEMBL466958 0.64 CHRM2 (0.88) CHRM2CHRM4CHRM5ADRA2AADRA2B
SCHEMBL287270 0.63 ALDH1A1 (0.47) ALDH1A1KDM4ECASP1NPC1RAB9A
Oxalic Acid SCHEMBL11194760 0.63 CHRM2 (0.42) CHRM2CHRM4CHRM5CHRM3
SCHEMBL11203775 0.62 DRD3 (0.40) HSD17B1HSD17B2
SCHEMBL467380 0.62 CHRM2 (1.00) CHRM2CHRM4CHRM5ADRA2AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427432-A2 NOVEL HETEROCYCLIC COMPOUNDS Torrent Pharmaceuticals Limited (IN) 2012-03-14 EP claimed
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS DUTT CHAITANYA (IN) 2012-02-23 US claimed
WO-2010128528-A2 NOVEL HETEROCYCLIC COMPOUNDS TORRENT PHARMACEUTICALS LIMITED (IN) 2010-11-11 WO claimed
EP-2427432-A2 NOVEL HETEROCYCLIC COMPOUNDS Torrent Pharmaceuticals Limited (IN) 2012-03-14 EP disclosed
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS DUTT CHAITANYA (IN) 2012-02-23 US disclosed
WO-2010128528-A2 NOVEL HETEROCYCLIC COMPOUNDS TORRENT PHARMACEUTICALS LIMITED (IN) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS AGER, REN, AGT CHRM2 2166/4885CHRM4 2027/4885CHRM5 1490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.